Authorities in Henan, China approved changes in Henan Taloph Pharmaceutical Stock's (SHA:600222) drug production license for its honeysuckle dew drops and isatis root syrup, according to a Tuesday filing with the Shanghai bourse.
The company obtained approval for in-house production of its dew drops and syrup, the filing said.
The honeysuckle dew is used for pediatric sores and summer heat, while the syrup is indicated for colds and sore throat.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.